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Abstract
Group B streptococcus (GBS) is a leading cause of infectious neonatal morbidity and mortality. Timely and accurate identiﬁcation of col-
onized mothers is imperative so that antibioprophylaxis can be implemented during labour to reduce the risk of neonatal sepsis. We
planned our study to analyse the diagnostic accuracy of an intrapartum PCR assay to identify GBS-colonized women and to allow the
implementation of correct (i.e. at least 4 h) intrapartum antibiotic prophylaxis based on the PCR results. We included 695 women in
labour who were tested for rectovaginal GBS carriage by culture and PCR. Women were also screened at 35–37 weeks of gestation.
Intrapartum GBS colonization was 19.3%. Assay sensitivity was 81.0% for antenatal culture and 85.0% for intrapartum PCR; p 0.72. GBS
colonization (n = 107) was known at least 4 h before delivery in 68 (64%) and 73 (68%) women based on antenatal culture and intra-
partum PCR, respectively. Among 43 women delivering preterm, correct status was known at least 4 h before delivery in 10 (23%) and
32 (74%) women according to antenatal culture and intrapartum PCR, respectively. These results support the concept that GBS screen-
ing can be performed routinely during labour in a clinical setting. The intrapartum approach is at least as accurate as the antenatal
screening, with the additional advantage of identifying women delivering preterm or not followed during pregnancy.
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Introduction
Group B streptococcus (GBS) is one of the leading causes of
neonatal sepsis [1–3]. There is evidence that intrapartum
antibiotic prophylaxis (IAP) decreases the risk of vertical
transmission of GBS as well as the risk of neonatal sepsis
[4,5]. GBS culture remains the reference standard for the
detection of GBS colonization, but it requires 24–72 h for
results to be known and thus precludes its use for intrapar-
tum screening. The Centers for Disease Control and Preven-
tion (CDC) and other societies currently recommend
antenatal screening with rectovaginal cultures and selective
IAP administration to GBS-positive women for a minimum of
4 h [6,7]. Adherence to these recommendations has
decreased the incidence of early-onset GBS disease (EOD)
from 1.5 to 0.5 per 1000 births [6,8]. Nevertheless, cases of
EOD still occur and involve in particular premature infants
and those born from mothers with negative antenatal GBS
cultures or who have received no prenatal care [9,10].
Several studies have shown a low sensitivity of antenatal
GBS cultures to detect colonization during labour [11–15]. It
has been reported that at least 10% of antenatal GBS-nega-
tive women turned positive at labour [9]. Based on current
guidelines, these women do not receive IAP and their neo-
nates are at risk of EOD [16]. Neonates born preterm are
at highest risk of EOD and their mothers receive IAP based
on the risk-factor strategy, without knowing whether they
are indeed colonized or not. However, the widespread use
of antibiotics is associated with maternal anaphylaxis [17]
and the selection of resistant strains of Escherichia coli [18–
20], not to mention economic costs.
Considerable efforts have been devoted to the develop-
ment of diagnostic tools for the identiﬁcation of GBS among
women in labour. Bergeron et al. demonstrated that a PCR
assay could detect genital GBS rapidly and reliably in this
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population [21]. However, the authors did not evaluate the
actual implementation of their assay in the labour room.
Recently, other rapid PCR assays for GBS detection have
been developed [22–24]. Among these, the Xpert GBS assay
(Cepheid, Sunnyvale, CA, USA) is performed on a platform
(GeneXpert Dx System) where sample preparation, ampliﬁ-
cation and detection steps are fully automated and com-
pletely integrated. This system has the potential to be used
outside the laboratory, thus providing diagnostic testing at
the point-of-care [23].
The objective of this study was to evaluate the diagnostic
accuracy of the intrapartum PCR performed by midwives, as
compared with the results of intrapartum culture and the
current recommended screening test (culture at 35–37
weeks). We investigated also the feasibility of implementing
IAP for at least 4 h based on the results of the intrapartum
PCR.
Materials and Methods
We conducted a prospective study among pregnant women
delivering in the University Hospitals of Geneva, Switzerland.
The study was approved by the institutional ethics commit-
tee and all women included gave written informed consent.
In a run-in phase from 4 December 2007 to 17 January
2008, midwives underwent training to uniformly collect sam-
ples and perform the PCR assay on a GeneXpert system
installed in the labour ward. Training and coaching was car-
ried out by two midwife coordinators. In the case of pro-
cessing problems or invalid results, a new training session
was conducted. During the run-in phase, women were
included if they had no exclusion criteria for GBS testing (i.e.
elective Caesarean section, a previous infant with GBS sepsis,
or a positive urinary culture for GBS during pregnancy) and
depending on the workload of the labour suite and the will-
ingness of the midwife. From 18 January 2008 to 4 April
2008, all delivering women without any of the above-men-
tioned exclusion criteria were considered for inclusion in the
study.
We collected demographic and obstetrical data for all
women. To assess feasibility (from 18 January), the following
data were also collected: reasons for not undergoing PCR
testing; time of arrival at the labour suite; time of sampling
and PCR result; time of delivery; administration and duration
of IAP; and neonatal data on GBS infection, antibiotic treat-
ment and intensive care unit admission.
Results from the overall study period were used to com-
pare the results of the antenatal culture (currently recom-
mended test) and intrapartum PCR (assessed strategy) with
those of the intrapartum culture (considered as the refer-
ence standard). To evaluate the feasibility of intrapartum
PCR testing for the implementation of IAP, only the results
from the second period (18 January onwards) were used
(Fig. 1).
Sample collection
We collected a rectovaginal swab from pregnant women at
35–37 weeks’ gestation, or before if hospitalized with pre-
term labour. Samples were taken using a COPAN 7LMR
(COPAN Diagnostics SpA, Brescia, Italy) and sent to the
microbiology laboratory for culture within 24 h. At admis-
sion for labour, a culture swab (COPAN 7LMR) and a dou-
ble PCR swab (Cepheid collection device) were collected by
the midwife. Sampling was performed on the lower third of
the vagina followed by the rectum. Culture samples were
FIG. 1. Flowchart of women included in the
study.
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collected in a uniform manner following CDC recommenda-
tions and sent to the laboratory. The two PCR swabs of the
collection devices were twirled around each other to mini-
mize swab-to-swab variation and the midwife immediately
processed one of the two swabs, whilst the other one was
stored at room temperature.
GBS culture in the microbiology laboratory
GBS detection by culture was carried out by inoculating in
Todd-Hewitt broth supplemented with antibiotics (TODD
H-T, BioMe´rieux, Marcy l’Etoile, France) and then subculture
on selective chromogenic agar (ChromID Strepto B Agar,
BioMe´rieux) at 35C for 24 h [25]. Identiﬁcation of suspect
colonies was further conﬁrmed by a streptococcal agglutina-
tion test (Slidex strepto Plus, BioMe´rieux) to ensure speciﬁc
identiﬁcation of GBS.
Rapid GBS PCR in the labour ward
The PCR GBS assay is performed on single-use cartridges
that include reagents for the simultaneous detection of the
3¢-DNA region adjacent to the cfb gene of GBS, a sample-
processing control to monitor processing conditions, and an
internal control to monitor PCR conditions and the absence
of reaction inhibition. The specimen and two reagents were
added to appropriate chambers of the cartridge. The total
hands-on time required for this manipulation was <2 min.
The cartridge was then inserted into the GeneXpert and
the run was started. The results were provided by the
GeneXpert system from measured ﬂuorescent signals using
embedded calculation algorithms. The test process required
approximately 75 min. In the case of an invalid result, the
midwife used the remaining second swab to repeat the PCR
test. If no result was obtained after two attempts, the test
was considered to be unresolved.
Intrapartum antibiotic prophylaxis and newborn follow-up
GBS-positive women identiﬁed by antenatal culture and/or
by intrapartum PCR received IAP. Women with unknown
GBS status received IAP based on risk factors (intrapartum
fever ‡38C; preterm delivery or rupture of membranes for
more than 18 h).
Newborns were admitted to special care when maternal
prophylaxis was incomplete and maternal risk factors were
present or if suspicion of infection. Antibiotic treatment was
given when clinical presentation was severe or deteriorating
or when additional biological evidence became available.
Diagnosis of sepsis was based on laboratory-conﬁrmed
bloodstream infections or clinical signs of sepsis according to
the CDC deﬁnitions. We disclosed the results of the intra-
partum culture and PCR to the paediatricians.
Statistical analysis
We calculated that we needed 700 women in order to recruit
140 GBS culture-positive women to show a statistically signiﬁ-
cant increase in sensitivity to detect maternal colonization
during labour from 80% by antenatal culture to 90% by intra-
partum PCR testing (alpha = 0.05 and power = 90%).
We estimated the sensitivity with a 95% conﬁdence inter-
val (95% CI) for the antenatal culture and the intrapartum
PCR compared with the intrapartum culture (reference stan-
dard) using the McNemar test among women with known
results. We decided not to report speciﬁcities as there is a
potential problem with the interpretation of the false-posi-
tive by PCR. Indeed, if culture is used as the reference stan-
dard, those considered as false-positive by PCR could well
be colonized as the PCR assay may better detect GBS than
the culture. Feasibility was tested by assessing the percentage
of intrapartum colonized women that would receive IAP for
at least 4 h before delivery.
Results are reported as proportions for discrete variables
and means and standard deviations (SD) for normally distrib-
uted continuous variables. Differences in proportions were
tested using Fisher’s exact test and in continuous variables
using the Student t-test. A p value of <0.05 was considered
signiﬁcant. Statistical data analysis was performed using SPSS
11.0 software (SPSS Inc, Chicago, IL, USA).
Results
During the run-in period, 132 women were included. From
18 January 2008 until the end of the study, 743 women deliv-
ered in our maternity unit, of whom 123 (16.6%) were non-
eligible for GBS screening. Among these, six were tested
(one had a prior newborn with GBS sepsis and ﬁve had a
positive urine culture) and their data used to test the diag-
nostic accuracy. Among the 626 eligible women for GBS
testing, 63 (10.2%) were not tested (80% due to admission
in advanced labour and 20% due to high workload). The ﬁnal
number of women included was 695 for diagnostic accuracy
and 557 for feasibility of the intrapartum strategy (Fig. 1).
Diagnostic accuracy
The mean maternal age was 30.5 years (SD = 5.4) and the
mean gestational age at delivery 39.5 weeks (SD = 1.8); 57%
were nulliparous and 7.5% delivered before 37 weeks’ gesta-
tion. Based on intrapartum culture, 19.3% were colonized.
Table 1 shows the characteristics of colonized and non-colo-
nized women.
Antenatal culture and intrapartum PCR showed a coloni-
zation rate of 19.6% and 19.8%, respectively. Sensitivity of
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the antenatal culture and the intrapartum PCR were not sig-
niﬁcantly different (81.0% [95% CI, 72.6–87.3] and 85.0%
[95% CI, 77.4–90.5], respectively; p 0.72) (Table 2). Forty-
eight women (7%) had discordant results between antenatal
and intrapartum culture (Table 3). Among them, ﬁve were
unresolved by PCR. The intrapartum PCR was in agreement
with the intrapartum culture in 62.8% (27/43) of these cases.
Agreement between results of the intrapartum culture and
the PCR was not affected by the status of the foetal mem-
branes (percentage of agreement, 94.9% when membranes
were intact and 92.7% when ruptured).
Feasibility
Among the 557 women included for feasibility, results of the
PCR were obtained at least 4 h prior to delivery in 426
(76.5%) women. The percentage of women requiring two
attempts to obtain a PCR result decreased during the study
period (13% at the beginning vs. 2% at the end), while the
percentage of unresolved results remained stable (3–5%).
One hundred and forty-ﬁve (26.0%) women received anti-
biotics during labour, 121 (83.4%) for EOD prevention.
Among these, 86 women (71%) received IAP for at least 4 h.
Forty-nine newborns were hospitalized in the neonatal unit
and 21 received antibiotics, but no case of neonatal sepsis
was diagnosed.
Among the 107 women colonized with GBS by intrapar-
tum culture, IAP was feasible for at least 4 h in 73 women
(68.2%) when based on PCR, and in 68 women (63.6%) when
based on antenatal cultures (p 0.54). Among 43 women
delivering preterm, 9 were colonized with GBS. Correct sta-
tus was known at least 4 h before delivery in 32 (7 positive
and 25 negative) by intrapartum PCR and in 10 women
(three positive and seven negative) by antenatal culture. All
women delivering preterm received IAP following current
recommendations.
Comment
Our study demonstrates the accuracy of a rapid PCR assay
to detect maternal GBS colonization during labour when
performed at the point-of-care by non-laboratory staff. The
test allows timely IAP in at least as many women as when
using antenatal cultures, with the additional advantage of
testing high-risk groups that are missed by antenatal cultures.
Strengths of our study were the high number of women
TABLE 1. Characteristics of GBS-
positive and GBS-negative women
on intrapartum culture
GBS-positive
n = 134 (19.3%)
GBS-negative
n = 561 (81.7%) p value
Nulliparity 76 (56.7%) 320 (57.0%) 1.0
Maternal age (years; mean, SD) 30.7 (5.6) 30.5 (5.4) 0.67
Gestational age at delivery (weeks; mean, SD) 39.4 (1.9) 39.5 (1.8) 0.82
Induced labour 62 (46.6%) 215 (7.3%) 0.09
Delivery before 37 weeks 11 (8.2%) 41 (7.3%) 0.72
ROM at admissiona 46 (34.3%) 189 (33.9%) 0.92
ROM > 18 h prior to deliverya 24 (17.9%) 93 (16.7%) 0.70
Caesarean section 20 (14.9%) 92 (16.4%) 0.79
Twins 2 (1.5%) 8 (1.4%) 1.0
GBS, Group B streptococcus; ROM, rupture of membranes.
aThree with missing data.
TABLE 2. Antenatal culture (35–37 weeks’ gestation) and
intrapartum PCR compared with the intrapartum culture
(reference standard)
Intrapartum culture
TotalPositive Negative
Antenatal culture Positive 98 25 123
Negative 23 483 506
Not done 13 53 66
Total 134 561 695
Intrapartum PCR Positive 108 18 126
Negative 19 492 511
Unresolveda 7 51 58
Total 134 561 695
aNo result was obtained after two attempts.
TABLE 3. Discordant Group B streptococcus results: (a)
discordant antenatal and intrapartum culture results; (b)
discordant intrapartum culture and PCR results
Number of
women PCR
Antenatal
culture
Intrapartum
culture Intrapartum
(a) Discordant antenatal and intrapartum cultures
10 Positive Negative Negative
12 Positive Negative Positive
3 Positive Negative Unresolveda
17 Negative Positive Positive
4 Negative Positive Negative
2 Negative Positive Unresolveda
(b) Discordant intrapartum PCR and intrapartum cultures
1 Not done Negative Positive
5 Negative Negative Positive
12 Positive Negative Positive
1 Not done Positive Negative
4 Negative Positive Negative
14 Positive Positive Negative
aNo result was obtained after two attempts.
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tested during labour by the midwives and the use of intra-
partum culture as the reference standard. On the other
hand, we were not able to show that the intrapartum strat-
egy better prevented neonatal sepsis, as there was no case
during the study.
The sensitivity of the intrapartum PCR to detect GBS
colonization during labour was slightly superior to antenatal
cultures, but the difference was not statistically signiﬁcant.
Other studies have reported higher sensitivities for the
same PCR assay [23,24,26], but the assay was either not
always carried out during labour or [24], when conducted
during labour, processed by specialized laboratory staff
[23,26]. An assay can be expected to better perform in
calm situations, rather than at the point-of-care with staff
dealing with urgent clinical situations. Because of logistics
issues (transportation, distance between the labour suite
and the laboratory, and absence of a laboratory technician
24/24 h), we could not send the samples to the laboratory
for immediate processing. Nevertheless, obtaining timely
results to allow prompt IAP should be the priority, despite
a possible loss of accuracy compared with the laboratory
performance of the assay.
In 7% (48) of cases, intrapartum PCR and antenatal cul-
tures did not match, thus conﬁrming that antenatal screening
does not necessarily identify intrapartum colonized women
[11,12,27,28]. Of these, 23 antenatal GBS-negative became
positive during labour and 25 antenatal GBS-positive became
negative. Some false-positive intrapartum PCR results may
indeed be true-positive, as two out of three had been colo-
nized by GBS on antenatal testing. A very low bacterial load
during labour may have precluded a positive culture, whereas
the PCR technique may in reality have been more sensitive
[29]. On the other hand, the difference between the intra-
partum culture and PCR may be explained by the double
sampling with optimized swabs for each method.
A clear advantage of the PCR assay is that it allows the
screening of women delivering preterm (10%) [16]. As less
mature newborns are at higher risk of EOD, but also for
development of bacterial resistance, this issue is clinically rel-
evant. In our study, only 20% of the women delivering pre-
term were GBS positive. PCR testing could have allowed
withholding antibiotic administration in two-thirds of these
women, thus improving the targeting of IAP and newborn
follow-up. The intrapartum PCR allowed us also to screen
women without prenatal care, a high-risk population with
elevated GBS colonization [16]. Although the percentage of
women without prenatal care is very low in our population,
geographical and socioeconomic factors in other settings
may considerably increase the size of this group and there-
fore the screening value of the test.
Around 10% of women were not tested, mostly due to
their arrival in advanced labour. During the study, IAP based
on antenatal GBS cultures was continued. Motivation of mid-
wives to perform the PCR may have been less when antena-
tal cultures were already available. We speculate that if only
PCR was performed, the percentage of women untested
would be lower. Based upon intrapartum PCR, a slightly
higher and non-signiﬁcant percentage of GBS-positive women
received IAP for at least 4 h compared with antenatal cul-
tures, and most GBS PCR-positive women (89.3%) received
antibiotic prophylaxis for at least 2 h. As colony counts of
GBS fall rapidly after 2 h antibiotic administration [30], ade-
quate protection against GBS infection may have been
achieved for most babies of PCR-screened mothers.
We have not performed a cost-beneﬁt analysis of rapid
PCR. Nevertheless, our results are in the estimate ranges
used in the study carried out by Haberland et al. [31], which
showed that the PCR-based strategy generates more beneﬁt
per birth than the antenatal culture strategy and resulted in
fewer courses of IAP and in fewer cases of EOD, infant
death and severe infant disability. Whether a PCR strategy
prevents more cases of GBS sepsis and at what cost needs
to be assessed.
In summary, GBS screening can be performed during
labour and it is at least as accurate as antenatal testing. The
intrapartum approach allows the identiﬁcation of high-risk
groups for neonatal sepsis, such as women delivering pre-
term or not followed during pregnancy. The time to switch
from a policy of antenatal testing to intrapartum testing has
probably arrived.
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